Anvimo 480mg Tablet

Anvimo 480mg Tablet is an antiviral medication containing letermovir as its active ingredient. It belongs to the pharmacological class of antiviral agents and is specifically classified under cytomegalovirus (CMV) DNA terminase inhibitors. Anvimo 480mg Tablet is primarily used for CMV prophylaxis in patients with CMV-seropositive status who have recently undergone allogeneic hematopoietic stem cell transplant (HSCT) and are at higher risk of CMV reactivation. Anvimo 480mg Tablet works by inhibiting the CMV DNA terminase complex, which is essential for viral replication. It is typically prescribed for CMV-seropositive adult patients following transplant to reduce the likelihood of viral complications. However, this medication is not indicated for treatment of active CMV infections. Patients taking this medication must observe strict safety precautions. Anvimo 480mg Tablet is contraindicated in individuals with known hypersensitivity to letermovir or any excipients. Additionally, concurrent use with certain medications is not recommended due to serious drug interactions. Caution is advised in pregnant or breastfeeding women, patients with hepatic impairment, and those consuming alcohol.

Anvimo 480mg Tablet is FDA-approved for the prevention of cytomegalovirus (CMV) infection in adult patients who: Have undergone allogeneic hematopoietic stem cell transplantation (HSCT) Are CMV-seropositive, meaning they have previously been exposed to the virus This medication is used prophylactically and should not be used to treat an active CMV infection.

Anvimo 480mg Tablet functions by blocking the CMV DNA terminase complex, a key component required for viral replication. Unlike conventional antiviral drugs that target DNA polymerase, this medication disrupts viral DNA processing and packaging, ultimately preventing the virus from multiplying and spreading in the body. By stopping CMV replication early in the process, this drug significantly lowers the risk of CMV disease in transplant recipients. The unique mechanism of action makes it highly effective while reducing the likelihood of cross-resistance seen with other CMV treatments. Due to its targeted action, it is well tolerated with a lower risk of severe toxicity compared to older antiviral medications.

The usual recommended dosage of Anvimo 480mg Tablet for CMV prophylaxis is 480 mg once daily. However, if taken in combination with cyclosporine, the dose is reduced to 240 mg daily to prevent excessive drug levels. This medication is available in oral tablets and intravenous (IV) infusion forms. Oral tablets should be swallowed whole with or without food, while the IV infusion must be administered under medical supervision to ensure proper dosing and monitoring.

Common Side Effects: Nausea Fatigue Headache Diarrhea Abdominal pain Serious Side Effects: Irregular heartbeat Swelling in legs or feet Unexplained bleeding or bruising Severe allergic reactions (rash, breathing difficulty)

Patients prescribed Anvimo 480mg Tablet should take it regularly to prevent CMV-related complications post-transplant. Always inform your doctor of any medications or supplements being taken to prevent harmful interactions. Missing doses can reduce the effectiveness of CMV prevention. Additionally, regular liver function tests may be required in certain patients.